CD1A and neoplasm: In this context, an anti-CD1a mAb named CR2113, has been demonstrated to induce potent ADCC in CD1a-expressing cell lines and T-ALL primary samples in vitro, which translated in anti-tumor activity against CD1a-expressing xenografts [63].